| Name | TAK-981 |
|---|---|
| Synonyms | MFCD32062692 |
| Description | TAK-981 is a first in class and selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities[1][2]. |
|---|---|
| Related Catalog | |
| Target |
SUMOylation[1]. |
| In Vitro | TAK-981 is able to increase the production of type 1 interferon (IFN), thereby increasing type 1 IFN-mediated signaling, activating innate effector cells and enhancing the antitumor innate immune responses[1]. |
| In Vivo | A single sub-cutaneous injection of TAK-981 in naive Balb/c mice at the brachial lymph nodes induces activation of DCs[2]. |
| References |
[1]. Sumoylation inhibitor TAK-981. [2]. TAK-981. |
| Density | 1.474±0.06 g/cm3(Predicted) |
|---|---|
| Boiling Point | 836.1±75.0 °C(Predicted) |
| Molecular Formula | C25H28ClN5O5S2 |
| Molecular Weight | 578.10 |
| Storage condition | 2-8°C |
| Hazard Codes | Xi |
|---|